drugset / Trial / NCT01830140

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT01830140

Phase 3 Completed 466 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

Timeline

Start
2013-07
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.01 %
Subject Bimatoprost Other / unclassified 0.03 %